Founded in Irvine, CA, TAE Life Sciences is a biotechnology firm dedicated to transforming cancer treatment through advanced radiation therapy. Their core mission is to make Boron Neutron Capture Therapy (BNCT) accessible and convenient for clinical use, offering a promising solution for previously untreatable cancers. The company focuses on developing the Alphabeam™ Neutron System and precision pharmacology to deliver boron drugs safely and effectively.
TAE Life Sciences has garnered attention from notable investors and industry experts, contributing to its rapid development. Though their devices and drugs are still in development and not yet available for commercial use, the company has made significant strides in the field of targeted radiotherapy. Their innovative approach holds the potential to revolutionize cancer care, providing safer and more effective treatment options for patients worldwide.
